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ABSTRACT
Osteoarthritis is a common degenerative joint disease for which
no disease-modifying drugs are currently available. Attempts to
treat the disease with small molecule inhibitors of the metal-
loproteinases that degrade the cartilage matrix have been
hampered by a lack of specificity. We aimed to inhibit cartilage
degradation by augmenting levels of the endogenous metal-
loproteinase inhibitor, tissue inhibitor of metalloproteinases
(TIMP)-3, through blocking its interaction with the endocytic
scavenger receptor, low-density lipoprotein receptor–related
protein 1 (LRP1). We discovered that suramin (C51H40N6O23S6)
bound to TIMP-3 with a KD value of 1.96 0.2 nM and inhibited its
endocytosis via LRP1, thus increasing extracellular levels of
TIMP-3 and inhibiting cartilage degradation by the TIMP-3 target
enzyme, adamalysin-like metalloproteinase with thrombospondin
motifs 5. NF279 (8,89-[carbonylbis(imino-4,1-phenylenecarbony-
limino-4,1-phenylenecarbonylimino)]bis-1,3,5-naphthalenetri-
sulfonic acid hexasodium salt), a structural analog of suramin,
has an increased affinity for TIMP-3 and increased ability to
inhibit TIMP-3 endocytosis and protect cartilage. Suramin is thus
a promising scaffold for the development of novel therapeutics
to increase TIMP-3 levels and inhibit cartilage degradation in
osteoarthritis.
Introduction
Osteoarthritis (OA) is a common degenerative joint disease,
in which cartilage degradation and subchondral bone remod-
eling cause pain and impaired movement of affected joints.
Themost common risk factors for OA are age, joint injury, and
obesity, which all alter the mechanical environment of the
joint and initiate catabolic joint remodeling. The disease is
estimated to affect 10% of men and 18% of women older than
60 years of age (Woolf and Pfleger, 2003), and its incidence is
predicted to rise with increasing population age and obesity.
No disease-modifying drugs are currently available, and
treatment is currently limited to management of symptoms
by analgesia or joint replacement surgery. There is thus a
significant clinical need for the development of novel thera-
peutic strategies.
Articular cartilage covers and protects the ends of bones in
articulating joints, enabling smooth, frictionless joint articu-
lation. Degradation of this cartilage layer is a key feature in
the pathogenesis of OA. Type II collagen and aggrecan are the
major components of the cartilage extracellular matrix, and
their degradation underlies the structural failure of the tissue.
Studies on transgenic mice have confirmed the central role of
two groups of related metalloproteinases in cartilage ma-
trix degradation: matrix metalloproteinases (MMPs), such as
MMP-13, degrade type II collagen (Little et al., 2009), whereas
adamalysin-like metalloproteinase with thrombospondin
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motifs (ADAMTS)-5 degrades aggrecan (Glasson et al., 2005;
Stanton et al., 2005). These enzymes are thus considered to be
potential therapeutic targets for OA, but their conserved
catalytic domains have hampered development of sufficiently
selective inhibitors to date.
We have adopted an alternative strategy of attempting to
block cartilage degradation by increasing levels of the endoge-
nous metalloproteinase inhibitor, tissue inhibitor of metallo-
proteinases (TIMP)-3, in the joint. The chondroprotective role of
TIMP-3 is illustrated by studies showing that mice lacking the
gene for Timp3 develop accelerated OA as they age (Sahebjam
et al., 2007) and, conversely, that recombinant TIMP-3 inhibits
development of OA in a rat model of disease (Black et al., 2006).
TIMP-3 levels are reduced in OA cartilage, although the mRNA
levels are not altered (Morris et al., 2010).
We found that TIMP-3 levels are primarily controlled post-
translationally and that TIMP-3 is readily endocytosed from
the extracellular environment by the endocytic scavenger re-
ceptor low-density lipoprotein receptor–related protein 1 (LRP1)
(Troeberg et al., 2008; Scilabra et al., 2013). We engineered
mutants of TIMP-3 that do not bind to LRP1, and showed that
they have a longer half-life in cartilage and protect cartilage
better than wild-type TIMP-3 (Doherty et al., 2016). Sulfated
glycosaminoglycans such as heparin, heparan sulfate, and
pentosan polysulfate (PPS) are also able to inhibit cartilage
degradation by inhibiting TIMP-3 binding to LRP1 and thus
increasing extracellular levels of TIMP-3 (Troeberg et al.,
2009, 2014; Scilabra et al., 2013). However, such sulfated
glycosaminoglycans have poor pharmacokinetics and limited
clinical scope. We thus sought to identify a small molecule
inhibitor of TIMP-3 endocytosis that could serve as a lead
compound for the development of novel OA therapeutics.
Yu et al. (2000) showed that TIMP-3 could be solubilized
from extracellular matrices by suramin, a historic antipara-
sitic and antihelminthic drug. Here we show that suramin
binds to TIMP-3 and inhibits its endocytosis by LRP1 and that
suramin blocks degradation of both normal porcine cartilage
and human OA cartilage in explant culture. We thus propose
that suramin is a promising scaffold from which to develop a
new type of therapeutic inhibitor to treat OA.
Materials and Methods
Materials. C-terminally FLAG-tagged human TIMP-3 was ex-
pressed in human embryonic kidney 293 cells and purified as pre-
viously described (Troeberg et al., 2009). Receptor-associated protein
was expressed inEscherichia coli and purified as described previously
(Yamamoto et al., 2013). C-terminally FLAG-tagged ADAMTS-5
lacking the C-terminal thrombospondin domain was expressed in
human embryonic kidney 293 cells and purified as previously de-
scribed (Gendron et al., 2007). The catalytic domains of MMP-1 and
MMP-3 were expressed in E. coli and purified as previously described
(Suzuki et al., 1998; Chung et al., 2000).
The following suramin hexasodium salt and suramin analogs were
from Tocris Bioscience (Bristol, UK): NF023 (8,89-[carbonylbis(imino-
3,1-phenylenecarbonylimino)]bis-1,3,5-naphthalene-trisulphonic
acid, hexasodium salt), NF110 (4,49,499,4999-[carbonylbis[imino-5,1,3-
benzenetriylbis(carbonylimino)]]tetrakisbenzenesulfonic acid tetrasodium
salt), NF157 [8,89-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-
fluoro-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic
acid hexasodium salt], NF279 (8,89-[carbonylbis(imino-4,1-phenylene-
carbonylimino-4,1-phenylenecarbonylimino)]bis-1,3,5-naphthalenetrisulfonic
acid hexasodium salt), NF340 [4,49-(carbonylbis(imino-3,1-(4-methyl-
phenylene)carbonylimino))bis(naphthalene-2,6-disulfonic acid) tetrasodium
salt], NF449 [4,49,499,4999-[carbonylbis(imino-5,1,3-benzenetriyl-
bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt],
and NF546 [4,49-(carbonylbis(imino-3,1-phenylene-carbonylimino-
3,1-(4-methyl-phenylene)carbonylimino))-bis(1,3-xylene-a,a9-diphosphonic
acid tetrasodium salt]. PPS was from Bene-PharmaChemie (Geretsried,
Germany). Amphotericin B and M2 anti-FLAG antibody were from
Sigma-Aldrich (Dorset, UK). TIMP-3 antibody (clone 183551, cat. no.
MAB973) and mouse IgG1 isotype control (clone 11711, cat. no.
MAB002) were from R&D Systems (Abingdon, UK), and anti-LRP1
(8G1, cat. no. ab20384) was from AbCam (Cambridge, UK). Quenched
fluorescent substrates for MMPs and ADAMTS-5 were from Bachem
(Bubendorf, Switzerland)
Dulbecco’s modified Eagle’s medium (DMEM), penicillin, strepto-
mycin, amphotericin, HEPES, and trypsin-EDTA were from PAA
Laboratories (Somerset, UK). Fetal calf serum (FCS) was from Gibco
(Paisley, UK). Eppendorf Protein LoBind tubes were from VWR (East
Grinstead, UK).
TIMP-3 Binding to Suramin and Analogs. Glycosaminoglycan-
binding ELISA plates (BD Life Sciences, Swindon, UK) were coated
with suramin or its analogs (10 mg/ml in Tris-buffered saline,
18 hours, 25°C) (Mahoney et al., 2004) and wells were blocked with
0.2% gelatin in PBS (1 hour, 37°C). Wells were washed in PBS
containing 0.1% Tween 20 after this and every subsequent step.
Purified FLAG-tagged human TIMP-3 (0.4–50 nM) in blocking
solution was applied to wells (3 hours, 37°C), and binding was
detected with anti-FLAG M2 primary antibody and anti-mouse
horseradish peroxidase–conjugated secondary antibody. 3,39,5,59-
Tetramethylbenzidine (Becton Dickinson, Swindon, UK) substrate
was added, the reaction was stopped when appropriate by adding
2 N H2SO4, and absorbance at 450 nm was measured using a FLUOstar
Omega microplate reader (BMG Labtech, Aylesbury, Buckinghamshire,
UK). Data (mean 6 S.E., n 5 3 technical repeats) were analyzed using
Prism7.0b software (GraphPadSoftware, LaJolla,CA) andEC50 values
determined using a one-site specific binding model. Flat planar
dimensions of suramin analogs were estimated using ICM-Pro software
(Molsoft LLC, San Diego, CA).
TIMP-3 Binding to LRP1. LRP1 (5 nM; BioMac, Leipzig,
Germany) was coated (overnight, 4°C) onto medium-binding ELISA
plates (Greiner Bio-One, Stonehouse, UK) in 20 mMHEPES, 150 mM
NaCl, 5 mM CaCl2, and 0.05% Tween 20, pH 7.4. Wells were blocked
with 10% bovine serum albumin (BSA) in Tris HCl, NaCl, and CaCl2
(TNC) buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 10 mM CaCl2,
and 0.05% Brij 35). Wells were washed in TNC buffer containing
0.1% Tween 20 after this and every subsequent step. FLAG-tagged
human TIMP-3 (0.4–50 nM), either alone or preincubated with
suramin (200 mg/ml, 1 hour, 37°C), was applied to wells in TNC
buffer containing 5% BSA (3 hours, 25°C). Binding was detected
with anti-FLAG M2 primary antibody and anti-mouse horseradish
peroxidase–conjugated secondary antibody in the same buffer.
3,39,5,59-Tetramethylbenzidine (Becton Dickinson) substrate was
added, the reaction was stopped when appropriate by adding
2NH2SO4, and absorbance at 450 nmwasmeasured using a FLUOstar
Omega microplate reader. Data (mean 6 S.D., n 5 3) were analyzed
using Prism 7.0b software.
Cell and Cartilage Explant Culture. HTB94 chondrosarcoma
cells (American Culture Type Collection, Manassas, VA) were main-
tained in DMEM with 10% FCS, 100 U/ml penicillin, and 100 U/ml
streptomycin at 37°C in 5% CO2.
Porcine and human cartilage explants and chondrocytes were
maintained in DMEM with 10% FCS, 100 U/ml penicillin, 100 U/ml
streptomycin, 2 mg/ml amphotericin B, and 10 mMHEPES at 37°C in
5% CO2. Porcine articular cartilage was dissected from metacarpo-
phalangeal joints of 3- to 9-month-old pigs within 24 hours of
euthanasia. Explants were prepared using a biopsy punch to ensure
uniformity of size and rested for 48 hours before use. Chondrocytes
were isolated by incubating dissected cartilagewith type 2 collagenase
(1 mg/ml; Worthington, Lakewood, NJ) in DMEM with 10% FCS
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(18 hours, 37°C). Cells were passed through a cell strainer andwashed
twice before plating.
Osteoarthritic human articular cartilage was obtained from pa-
tients undergoing knee replacement surgery. Tissue samples were
obtained from the Oxford Musculoskeletal Biobank (Oxford, UK) and
were collected with informed donor consent in full compliance with
national and institutional ethical requirements, the United Kingdom
Human Tissue Act, and the Declaration of Helsinki (HTA license
12217 and Oxford REC C 09/H0606/11). Human cartilage explants
and chondrocytes were prepared as described for porcine cartilage
above.
TIMP-3 Endocytosis Assays. Cells (HTB94 chondrosarcoma
cells, primary porcine chondrocytes, or human osteoarthritic chon-
drocytes) were plated overnight (6  105 cells per well of a 12-well
plate) in DMEM containing 10% FCS and washed three times in
serum-free DMEM.
To evaluate endocytosis of exogenously added TIMP-3, cells were
incubated with recombinant TIMP-3 (1 nM in 1.5mlDMEMwith 0.1%
FCS) for 0–24 hours. Conditioned media were concentrated by
precipitation with trichloroacetic acid [5% (v/v), 4°C, 18 hours]. After
centrifugation (13,000 rpm, 4°C, 10 minutes), protein-containing
pellets were resuspended in SDS sample buffer (30 ml), electro-
phoresed (7 ml) on a 10% polyacrylamide gel, and immunoblotted onto
polyvinylidene fluoride. After blocking in 5% (m/v) BSA in Tris-
buffered saline, TIMP-3 levels were analyzed using an M2 anti-
FLAG antibody (Sigma-Aldrich), an alkaline phosphatase–conjugated
anti-mouse secondary antibody (Promega, Southampton, UK), and a
Western Blue stabilized substrate for alkaline phosphatase (Promega).
Immunoblots were analyzed by densitometry using Phoretix 1D
densitometry software (TotalLab, Newcastle-upon-Tyne, UK), and
TIMP-3 remaining in the medium (mean6 S.D., n5 3) was calculated
relative to pixel volume at a t of 0 hours (defined as 100%).
To evaluate accumulation of endogenous TIMP-3, cells were in-
cubated with suramin (50–200 mg/ml) in serum-free DMEM for
30 hours. Media were harvested, precipitated with trichloroacetic
acid, and analyzed by immunoblotting using a rabbit anti–TIMP-3
polyclonal antibody (AB6000; Millipore, Hertfordshire, UK) and an
alkaline phosphatase–conjugated anti-rabbit secondary antibody
(Promega). TIMP-3 in themedium (mean6S.D., n5 3)was calculated
relative to the pixel volume of untreated cells (defined as 1).
mRNA Analysis. HTB94 chondrosarcoma cells or primary human
chondrocytes (1 106 cells) were treated in triplicate with 0–250 mg/ml
suramin in serum-free DMEM for 18–48 hours. Total RNA was
isolated from cells using an RNeasy mini kit (Qiagen, Crawley, UK)
and cDNA was synthesized (reverse transcriptase kit; Applied
Biosystems, Foster City, CA). Levels of TIMP-1, TIMP-2, TIMP-3,
LRP1, and RPLP0 internal reference mRNA were quantified by real-
time polymerase (60S acidic ribosomal protein P0) chain reaction
on a Corbett Rotor-Gene 6000 (Corbett Life Science, Mortlake, NSW,
Australia) using TaqMan Fast Universal PCR Master Mix (Applied
Biosystems) and TaqMan probes (Applied Biosystems) Hs01092512_g1
for TIMP-1, Hs00234278_m1 for TIMP-2, Hs00165949_m1 for TIMP-3,
Hs00233856_m1 for LRP1, and Hs99999902_m1 for RPLP0. The DD
threshold cycle values (mean 6 S.D., n 5 3 technical replicates) are
shown relative to control untreated HTB94 cells (defined as 1).
Cartilage Explant Cultures. The effects of suramin on cartilage
degradation were assessed using porcine or human cartilage explants.
Explants were rested for 48 hours after dissection and were washed
with serum-free DMEM. Explants were then treated with retinoic
acid (1 mM; Sigma-Aldrich), interleukin (IL)-1 (10 ng/ml; Peprotech,
London, UK), and/or suramin (0–250 mg/ml) in serum-free DMEM for
48 hours.
Aggrecan degradation was analyzed by quantifying aggrecan
fragments released into the conditioned media using the dimethyl-
methylene blue (DMMB) dye-binding assay (Farndale et al., 1986)
(mean 6 S.D., n 5 3) and by immunoblotting with neo-epitope
antibodies that recognize ADAMTS-cleaved but not intact aggrecan.
For immunoblotting, conditioned media were deglycosylated by
adding an equal volume of 200 mM sodium acetate and 50 mM
Tris/HCl, pH 6.8, containing chondroitinase and b-endoglycosidase
(0.05 U each; 18 hours, 37°C; Sigma-Aldrich). Aggrecan fragments
were precipitated by adding five volumes of ice-cold acetone
(18 hours, 220°C). After centrifugation (13,000 rpm, 10 minutes,
4°C), pellets were resuspended in SDS sample buffer, separated by
electrophoresis on a 6% (v/v) polyacrylamide gel, and blotted onto
polyvinylidene fluoride. Membranes were blocked with 5% (m/v)
BSA in Tris-buffered saline and incubated with either a rabbit
antibody that recognizes the AGEG neo-epitope generated by ADAMTS
cleavage of the TAQE1771∼1772AGEG bond of aggrecan (Troeberg et al.,
2008) or a mouse antibody that recognizes the ARGSV neo-epitope
generated by ADAMTS cleavage of the NITEGE373∼374ARGSV bond
(Hughes et al., 1995).
Cell Viability Assays. HTB94 chondrosarcoma cells or human
OA chondrocytes (103 cells per well in 96-well plates) were plated
overnight in DMEM with 10% FCS. Cells were washed in serum-free
cartilage medium and treated for 48–72 hours with suramin (0–250
mg/ml) or sodium nitroprusside (10 mM) as a control to induce cell
death. Cell viability was then assessed using the 3-(4,5-dimethylthi-
azol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
CellTiter Cell Proliferation Assay (Promega) according to the manufac-
turer’s instructions (mean 6 S.D., n 5 3).
TIMP-3 Inhibition of Target Metalloproteinases. The inhibi-
tion constant, Ki(app), for TIMP-3 inhibition of ADAMTS-5, MMP-1,
and MMP-3 was determined under equilibrium kinetic conditions
using the tight binding equation (Bieth, 1995). TIMP-3 (0.5 nM) was
incubated with the target metalloproteinase (0.5 nM ADAMTS-5 or
MMP-1) and/or suramin (0.05 mg/ml) or PPS (0.05 mg/ml) for 1 hour at
37°C, and residual enzyme activity against a quenched fluorescent
substrate was determined. ADAMTS-5 activity was monitored using
20 mM ortho-aminobenzoyl-Thr-Glu-Ser-Glu∼Ser-Arg-Gly-Ala-Ile-
Tyr-(N-3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)-Lys-Lys-NH,
and MMP-1 and MMP-3 activity was monitored using 1.5 mM
7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-(N-3-[2,4-dinitro-
phenyl]-L-2,3-diaminopropionyl)-Ala-Arg-NH2, as described previously
(Troeberg et al., 2009). Steady-state velocities were determined using a
Gemini microplate spectrofluorimeter (Molecular Devices,Wokingham,
UK). Ki(app) (mean 6 S.D., n 5 3–5 independent experiments) was
calculatedusingGraphPadPrism7.0b to fit thedata to the tight binding
equation as follows (Bieth, 1995):
vs
vo
512
ðEo1 Io1KiðappÞ2 ½ðEo1 Io1KiðappÞÞ224EoKiðappÞ
1
2
2Eo
where vo is the equilibrium rate of substrate hydrolysis in the
absence of inhibitor, Eo is the total enzyme concentration, Io is the
total inhibitor concentration, and Ki(app) is the apparent inhibition
constant.
Results
Suramin Inhibits the Endocytosis of TIMP-3 by the
LRP1 Scavenger Receptor. As a first step to evaluating
the effect of suramin on TIMP-3 endocytosis by the scavenger
receptor LRP1, we examined TIMP-3 binding to immobilized
suramin in a solid-phase binding assay. TIMP-3 bound
strongly to suramin, with a KD value of 1.9 6 0.2 nM (Fig.
1A). TIMP-3 also bound strongly to immobilized LRP1 (Fig.
1B), and this binding was abolished when TIMP-3 was
preincubated with suramin (200 mg/ml; Fig. 1B).
We previously showed that the rate of TIMP-3 endocytosis
by LRP1 can be quantified by adding purified FLAG-tagged
recombinant TIMP-3 (1 nM) to HTB94 chondrosarcoma cells
and monitoring its disappearance from the medium (Doherty
et al., 2016). In the absence of suramin, TIMP-3 was taken up
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Fig. 1. Suramin binds to TIMP-3 and inhibits its cellular endocytosis by LRP1. (A) Glycosaminglycan-binding 96-well plates were coated with suramin
(10mg/ml in PBS, filled circles) or PBS (open circles) and blocked in 0.2% gelatin in PBS.Wells were then incubated with TIMP-3 (0.4–50 nM) and binding
was detected using anM2 anti-FLAG antibody (mean6S.D., n = 3). (B)Medium-binding 96-well ELISA plates were coated with LRP1 (5 nM) and blocked
with 10%BSA in TNC buffer.Wells were then incubated with TIMP-3 (0.4–50 nM), either alone (open circles) or preincubatedwith suramin (filled circles,
200 mg/ml, 1 hour, 37°C) and binding was detected using an M2 anti-FLAG antibody (mean 6 S.D., n = 3). (C) HTB94 cells were incubated with
recombinant TIMP-3 (1 nM) or TIMP-3 preincubated with suramin (200 mg/ml, 1 hour, 37°C) for 0–8 hours and TIMP-3 remaining in the medium was
analyzed by immunoblotting and densitometry (mean 6 S.D., n = 4). TIMP-3 (open circles) was taken up from the medium with a half-life of 4.0 6 1.3
hours, whereas TIMP-3 preincubated with suramin (filled circles) was minimally endocytosed. (D) HTB94 chondrosarcoma cells were incubated with
suramin (50–200 mg/ml) in serum-free DMEM for 30 hours. Conditionedmedia were concentrated by TCA precipitation and TIMP-3 levels were analyzed
by immunoblotting and densitometry. Values are expressed relative to the amount of TIMP-3 in themedium of untreated cells, defined as 1 (mean6 S.D.,
n = 5; ***P # 0.001 by one-way ANOVA with Bonferroni’s correction). (E) HTB94 chondrosarcoma cells were treated with suramin (0–250 mg/ml,
18 hours) and expression of TIMP-3 mRNA was analyzed by quantitative PCR relative to RPLP0. TIMP-3 expression in the absence of suramin was
defined as 1 (mean6 S.D., n = 3, P. 0.05 by one-way ANOVAwith Bonferroni’s correction). (F) HTB94 cells were treated with suramin (0–250 mg/ml) or
sodium nitroprusside (10 mM) for 72 hours and cell viability was assessed using MTS (mean 6 S.D., n = 3; ***P # 0.001 by one-way ANOVA with
Bonferroni’s correction). (G) Primary chondrocytes were isolated from human OA or porcine cartilage and incubated with suramin (0–250 mg/ml) in
serum-free DMEM for 48 hours. Conditioned media were concentrated by TCA precipitation and TIMP-3 levels were analyzed by immunoblotting. (H)
HumanOA chondrocytes were treatedwith suramin (0–250mg/ml, 48 hours) and expression of TIMP-3mRNAwas analyzed by quantitative PCR relative
to RPLP0, with expression in the absence of suramin defined as 1 (n = 5 donors, mean6 S.D., P. 0.05 by one-way ANOVA with Bonferroni’s correction).
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from the medium with a half-life of 4.0 6 1.3 hours (Fig. 1C).
Preincubation of TIMP-3 with suramin (200 mg/ml, 1 hour,
37°C) markedly inhibited this uptake; more than 85% of
TIMP-3 remained in the medium after 8 hours and a half-
life could not be accurately calculated.
Suramin also inhibited endocytosis of endogenously
expressed TIMP-3 in HTB94 cells. No TIMP-3 was detectable
in the medium of untreated HTB94 cells, but TIMP-3 accumu-
lated when cells were treated with suramin (50–200mg/ml; Fig.
1D). This increase in TIMP-3 in themediumwas not associated
with any significant change in TIMP-3 mRNA levels (Fig. 1E).
Suramin had no effect on cell viability, in contrast with sodium
nitroprusside, a known cytotoxic agent (Fig. 1F).
Suramin similarly inhibited endocytosis of endogenously
expressed TIMP-3 in primary chondrocytes isolated from
human OA cartilage or normal porcine cartilage (Fig. 1G),
without any significant change in TIMP-3 mRNA levels (Fig.
1H) or cell viability (Fig. 1I).
Suramin had no effect on TIMP-1 or TIMP-2 mRNA levels in
HTB94 cells (Fig. 2,A andB). Expression of LRP1wasunaffected
by suramin at concentrations up to 200 mg/ml, although a 3-fold
increase in expressionwas detected at 250mg/ml (P, 0.001; Fig.
2C). Shedding of LRP1 ectodomain into themediumwas also not
affected by suramin (50–250 mg/ml; Fig. 2D).
Suramin Does Not Alter TIMP-3 Activity. We evalu-
ated whether TIMP-3 binding to suramin had any effect on its
inhibition of target metalloproteinases in vitro. ADAMTS-5 is
considered to be the primary aggrecan-degrading enzyme in
murine (Glasson et al., 2005; Stanton et al., 2005) and human
(Ismail et al., 2015) cartilage. TIMP-3 had an apparent affinity
constant, Ki(app), of 2.03 6 0.65 nM for ADAMTS-5 in the
absence of suramin (Fig. 2E), in line with previous reports
(Doherty et al., 2016). Preincubation of TIMP-3 with suramin
had no significant effect on this affinity, with aKi(app) of 1.606
0.62 nM (Fig. 2E). In contrast, PPS reduced Ki(app) to a value
too low to be calculated (Fig. 2E), as previously reported
(Troeberg et al., 2012).
Suramin also had no effect on TIMP-3 affinity for MMP-1,
with aKi(app) of 0.666 0.16 nM in the absence of suramin (Fig.
2F) and 0.65 6 0.09 nM in the presence of suramin (Fig. 2F).
Affinity for MMP-3 was similarly unaffected, with a Ki(app) of
1.146 0.93 nM in the absence of suramin and 0.766 0.09 nM
in the presence of suramin.
Suramin Inhibits Cartilage Degradation. The effect of
suramin on cartilage degradation was evaluated by measuring
its effect on aggrecan release from cartilage explants in vitro.
Explants of human knee cartilage were obtained at the time of
joint replacement surgery for OA. Treatment of the explants
with IL-1 or retinoic acid stimulated matrix catabolism, with
theDMMBassay indicating a 2- to 3-fold increase in the amount
of aggrecan released into the conditioned medium (Fig. 3, A and
C). This aggrecan degradation was dose-dependently inhibited by
suramin, with an IC50 of 626 16 mg/ml (Fig. 3C). Similar efficacy
was observed in cartilage from five other donors.
Suramin also effectively inhibited aggrecan release from
IL-1 or retinoic acid–stimulated porcine cartilage explants,
with an IC50 of 98 6 9 mg/ml (Fig. 3D). Immunoblotting with
the anti-ARGSV and anti-AGEG neo-epitope antibodies showed
that suramin inhibited aggrecan degradation at the ADAMTS-
susceptible NITEGE373∼374ARGSV and TAQE1771∼1772AGEG
sites (Fig. 3E), indicating that aggrecanase activities were
blocked.
To investigate whether protection by suramin was depen-
dent on TIMP-3, we stimulated cartilage with retinoic acid
and added suramin in combination with a TIMP-3 antibody or
an isotype control antibody. In the presence of the isotope
antibody, suramin significantly inhibited aggrecan release
(Fig. 3F). However, in the presence of the anti–TIMP-3
antibody, suramin was unable to inhibit aggrecan degradation.
Suramin Analog NF279 Shows Improved Efficacy. To
further understand themode of suramin action and to identify
additional bioactive compounds, we tested the ability of seven
commercially available suramin analogs (NF023, NF110,
NF157, NF279, NF340, NF449, and NF546) to inhibit carti-
lage degradation. Porcine cartilage explants were stimulated
with retinoic acid in the presence of 200 mg/ml suramin or a
suramin analog for 48 hours, and cartilage degradation was
quantified using the DMMB assay. NF279 showed markedly
improved activity, inhibiting both retinoic acid–stimulated
and unstimulated release of aggrecan fragments (Fig. 4A),
with an IC50 of 15.6 6 10 mg/ml.
The affinity of the analogs for TIMP-3was evaluated using a
solid-phase binding assay. NF279 had the highest affinity for
TIMP-3, with a KD value of 0.85 6 0.09 nM (Fig. 1A). NF157
had similar affinity for TIMP-3 (KD 5 1.5 6 0.11 nM) as was
seen for suramin (KD 5 1.9 6 0.2 nM, as in Fig. 1A), with the
remaining analogs showing lower affinity than suramin.
The ability of the analogs to promote TIMP-3 accumulation
was assessed by incubating HTB94 chondrosarcoma cells with
suramin or the suramin analogs (200 mg/ml) for 36 hours and
quantifying TIMP-3 levels in the medium by immunoblotting.
The highest levels of TIMP-3 accumulated in cells treatedwith
NF279 (233% 6 73% relative to suramin, defined as 100%;
Fig. 4C). NF340 and NF546 showed minimal efficacy.
A strong exponential correlation was observed between the
level of TIMP-3 accumulation (relative to suramin, defined
as 100%) and the log10 of analog affinity for TIMP-3, with an r
of 20.8654 (P 5 0.0119; Fig. 4D). The level of TIMP-3 accumu-
lation negatively correlated with aggrecan release, although
this was nonsignificant (r 5 20.6238, P 5 0.0984; Fig. 4E).
Discussion
OA has long been thought of a disease arising from passive
wear and tear of the joints and as an inevitable consequence of
aging. However, studies on knockout mice over the last decade
have conclusively shown that OA is an active disease, in which
various risk factors stimulate the cells in joint tissues to
increase their catabolic activity. The roles of metalloprotein-
ases in cartilage degradation are well established, with
MMP-13 known to drive cleavage of type II collagen (Little
et al., 2009) and ADAMTS-5 known to drive cleavage of
aggrecan (Glasson et al., 2005; Stanton et al., 2005). The
endogenous inhibitor of these enzymes, TIMP-3, is an
(I) Human OA chondrocytes were treated with suramin (0–250 mg/ml) and/or retinoic acid (1 mM) for 48 hours and cell viability assessed using MTS
(mean6 S.D., n = 3 donors,P. 0.05 by two-way ANOVAwith Bonferroni’s correction). MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium; PCR, polymerase chain reaction; RA, retinoic acid; SNP, sodium nitroprusside; TCA, trichloroacetic acid.
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important chondroprotective molecule, with Timp3-null ani-
mals developing accelerated OA (Sahebjam et al., 2007). The
observation that TIMP-3 levels are reduced in human OA
cartilage (Morris et al., 2010) led us to examine the molecular
mechanisms regulating TIMP-3 levels, and it also led to the
discovery that TIMP-3 is regulated post-translationally by
endocytosis via the scavenger receptor LRP1 (Troeberg et al.,
2008; Scilabra et al., 2013).
We recently engineered LRP1-resistant mutants of TIMP-3
and found that these have a longer half-life in cartilage and
inhibit cartilage degradation at lower concentrations and for
longer than wild-type TIMP-3 (Doherty et al., 2016). This
illustrates that targeting the TIMP-3 endocytosis pathway is a
potential strategy for inhibiting cartilage loss in OA. Admin-
istration of recombinant protein is unlikely to be a feasible
therapeutic option for OA treatment, so we sought to develop
small molecule inhibitors of TIMP-3 endocytosis that could
increase levels of the endogenous inhibitor in cartilage. We
show here that suramin, a polysulfonated naphthalene de-
rivative of urea, binds to TIMP-3 and inhibits its endocytic
uptake by cells through the LRP1 scavenger receptor, inhibit-
ing degradation of aggrecan by ADAMTSs in cartilage.
TIMP-3 has a region of basic amino acids on its surface, and
lysine and arginine residues in this area have been shown to
mediate binding to sulfated proteoglycans (Lee et al., 2007;
Troeberg et al., 2012) and LRP1 (Doherty et al., 2016). Suramin
is likely to interact with this region of TIMP-3 via its nega-
tively charged polysulfonated naphthylamine groups and hence
to block interaction with LRP1. This basic region is on the
opposite side of TIMP-3 to the one that interacts with target
metalloproteinases, suggesting that suramin should not im-
pair TIMP-3 inhibition of metalloproteinases. Indeed, we found
that suramin had no effect on TIMP-3 affinity for ADAMTS-5,
MMP-1, and MMP-3 in vitro. We previously found that sulfated
molecules like heparin, heparan sulfate and PPS could increase
TIMP-3 affinity for ADAMTS-4 andADAMTS-5 (Troeberg et al.,
2008, 2012, 2014), but this was not observed for suramin. This is
likely because suramin is too short to simultaneously bind to
basic regions on TIMP-3 and the enzymes and thus is unable to
support formation of high-affinity trimolecular complexes.
Fig. 2. Suramin does not impair inhibitory activity of TIMP-3. (A) HTB94 cells were incubated with suramin (0–250 mg/ml, 18 hours) and expression of
TIMP-1 mRNAwas analyzed by quantitative PCR relative to RPLP0. TIMP-1 expression in the absence of suramin was defined as 1 (mean6 S.D., n = 3,
P . 0.05 by one-way ANOVA with Bonferroni’s correction). (B) HTB94 cells were incubated with suramin (0–250 mg/ml, 18 hours) and expression of
TIMP-2 mRNAwas analyzed by quantitative PCR relative to RPLP0. TIMP-2 expression in the absence of suramin was defined as 1 (mean6 S.D., n = 3,
P. 0.05 by one-way ANOVAwith Bonferroni’s correction). (C) HTB94 cells were incubated with suramin (0–250mg/ml, 18 hours) and expression of LRP1
mRNA was analyzed by quantitative PCR relative to RPLP0. LRP1 expression in the absence of suramin was defined as 1 (mean 6 S.D., n = 3; ***P #
0.001 by one-way ANOVAwith Bonferroni’s correction). (D) HTB94 cells were treated with suramin (0–250 mg/ml, 30 hours), and conditionedmedia were
concentrated by TCA precipitation and analyzed by immunoblotting using an 8G1 anti-LRP1 antibody. (E) ADAMTS-5 (0.5 nM) was incubated (1 hour,
37°C) with TIMP-3 (0.5–5 nM) and combinations of suramin (0.05 mg/ml) or PPS (0.05 mg/ml). Residual activity against a fluorescent peptide substrate
was determined, and Ki(app) values (expressed in nM) were calculated from equilibrium rates of substrate hydrolysis using the tight binding equation
(mean6 S.D., n = 4–5; *P# 0.05 by one-way ANOVAwith Bonferroni’s correction). (F) TIMP-3 (0.3–50 nM)was incubated (1 hour, 37°C) withMMP-1 (0.5
nM) or MMP-3 (1 nM) in the presence or absence of suramin (0.05 mg/ml). Residual activity against a fluorescent peptide substrate was determined,
and Ki(app) values (expressed in nM) were calculated from equilibrium rates of substrate hydrolysis using the tight binding equation (mean6 S.D., n = 3;
P . 0.05 by Student’s t test). ns, not significant.
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Fig. 3. Suramin inhibits aggrecan degradation in retinoic acid–stimulated porcine and human cartilage explants. (A) Human OA cartilage explants
were stimulated with IL-1 (10 ng/ml) in the presence of suramin (0–100 mg/ml) for 48 hours and degraded aggrecan fragments released into the
conditionedmedium quantified using the DMMBassay (mean6 S.D., n = 3; *P# 0.05; ***P# 0.001 by two-way ANOVAwith Bonferroni’s correction).
(B) Porcine cartilage explants were stimulated with IL-1 (10 ng/ml) in the presence of suramin (0–250 mg/ml) for 48 hours and degraded aggrecan
fragments released into the conditioned medium were quantified using the DMMB assay (mean6 S.D., n = 3; ***P# 0.001 by two-way ANOVA with
Bonferroni’s correction). (C) Human OA cartilage explants were stimulated with retinoic acid (1 mM) in the presence of suramin (0–200 mg/ml) for
48 hours and degraded aggrecan fragments released into the conditionedmediumwere quantified using the DMMB assay (mean6 S.D., n = 3; ***P#
0.001 by two-way ANOVA with Bonferroni’s correction). (D) Porcine cartilage explants were stimulated with retinoic acid (1 mM) in the presence of
suramin (0–250 mg/ml) for 48 hours and degraded aggrecan fragments released into the conditioned medium were quantified using the DMMB assay
(mean6 S.D., n = 3; ***P# 0.001 by two-way ANOVAwith Bonferroni’s correction). (E) Conditioned media from (D) were analyzed using neo-epitope
antibodies that recognize the 1772AGEG or 374ARGSV termini generated by ADAMTS cleavage of aggrecan. (F) Porcine cartilage was incubated with
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Previous crystallography studies indicated that LRP1 li-
gands bind to the receptor through a pair of lysine residues
21Å apart, which interact with two acidic pockets on sequential
complementary repeats of LRP1 (Fisher et al., 2006). Mutation
of several lysine residues on receptor-associated protein, a
prototypic LRP1 ligand, reduce binding to LRP1, indicating
that the extended charge landscape is important for orienting
the two lysine residues that interact with the complementary
repeat pockets (van den Biggelaar et al., 2011; Dolmer et al.,
2013; Prasad et al., 2016). Our mutagenesis study of TIMP-3
supports this model, with LRP1 binding being reduced by
mutation of several pairs of lysine residues separated by 21 6
5 Å (Doherty et al., 2016). In an extended flat planar confor-
mation, suramin has an estimated maximal length of 38 Å.
Although the molecule is likely to adopt numerous confor-
mations in solution, this indicates it is of sufficient length for
the two clusters of sulfonate groups on either end of the
suramin molecule to bind to the LRP1-interacting dilysine
motif on TIMP-3 and thus to block TIMP-3 interaction with
the endocytic receptor.
We evaluated seven commercially available suramin ana-
logs and found that NF279 exhibited an improved chondro-
protective activity, with a 6-fold improved IC50 value of 15 mg/ml
(11.6 mM). This correlated with an increased affinity for
TIMP-3 and accumulation of higher TIMP-3 levels in NF279-
treated cells. The structure of NF279 is very similar to that
of suramin, with two clusters of sulfonate groups at each end of
the molecule (Fig. 4F) and an estimated maximal length of
39 Å in an extended planar conformation, suggesting that it
has a similar binding mode to suramin. Shorter analogs (e.g.,
NF340 with an estimated maximal length of 23 Å) and or
analogs with fewer sulfonate groups (e.g., NF546) were less
effective at protecting cartilage and supporting TIMP-3
accumulation. NF279 may adopt a more extended conforma-
tion in solution than suramin, since the phenyl links in the
middle of the compound are in para, rather than meta,
orientations. This may enable NF279 to more effectively
bridge LRP1-interacting residues on TIMP-3. Further analogs
will need to be evaluated to improve understanding of the
structure-activity relationship of the suramin scaffold.
Suramin has been shown to ameliorate cartilage damage in
a rat inflammatory arthritis model of rheumatoid arthritis
(Sahu et al., 2012), with reduced levels of proinflammatory
cytokines in the plasma and joints of treated animals.
Although OA is associated with metalloproteinase degradation
of cartilage extracellular matrix components, rheumatoid
arthritis is an inflammatory disease driven by proinflam-
matory cytokines, such as tumor necrosis factor (TNF) and
IL-1. TIMP-3 inhibits release of active TNF by inhibiting
the activity of the metalloproteinase A Disintegrin and
Metalloproteinase 17 (ADAM17, or TNFa-converting enzyme)
(Mohammed et al., 2004), so we hypothesize that suramin also
protected cartilage in this inflammatory arthritis model by
blocking endocytosis of TIMP-3 by LRP1. Although the
pathologic role of inflammation in OA is speculative rather
than proven, suramin’s ability to inhibit inflammation as well
as metalloprotease-driven cartilage breakdown is likely to
further augment its chondroprotective effect.
Suramin has been shown to have several biologic effects, so it
is possible that suramin protects cartilage through molecular
mechanisms other than inhibiting TIMP-3 endocytosis. Since its
development in 1916, suramin has been used to treat human
infection with protozoan Trypanosoma and helminthic Oncho-
cerca parasites (Hawking, 1978; Voogd et al., 1993). Its mecha-
nism of antiparasitic action is unclear. Suramin inhibits several
trypanosomal glycolytic enzymes in vitro (Misset andOpperdoes,
1987) and reduces ATP generation in vivo (Fairlamb and
Bowman, 1980). Suramin has been shown to inhibit MMP-9
activity (Taniguti et al., 2012), and we found that it can also
inhibitMMP-2 activity in vitro (data not shown). This is unlikely
to contribute to the chondroprotection we observed in this study,
in which cartilage degradation in the first 1–3 days after explant
stimulation was mediated by ADAMTSs, with MMP-dependent
degradation only evident after 14–21 days (Pratta et al., 2003;
Lim et al., 2010). Suramin is also known to antagonize ATP
purinergic signaling through the P2X receptor (Dunn and
Blakeley, 1988). NF279 is less effective than suramin at inhibit-
ing purinergic signaling in chondrocytes (Varani et al., 2008), so
its increased chondroprotection argues against P2X antagonism
being the primary mechanism of suramin chondroprotective
action. It is likely that suramin will have additionalmechanisms
of action in vivo, but our observation that the protective effects of
suramin were inhibited by a TIMP-3 blocking antibody suggest
that TIMP-3 is required for suramin’s chondroprotective effect
and that analogs with improved ability to block TIMP-3 uptake
will have improved ability to protect cartilage.
Suramin is not orally bioavailable (Voogd et al., 1993) and
violates several of Lipinski’s rule of 5. It has a molecular mass
of 1297 g/ml, more than five hydrogen bond donors, and more
than 10 hydrogen bond donors. Patients with OA are com-
monly treated with intra-articular injection of corticosteroids,
indicating that intra-articular administration of suramin is
feasible. Further development of orally bioavailable suramin
analogs could be pursued by “lead-hopping” to a smaller
chemical series once structure-activity relationships are more
fully understood.
Suramin’s clinical use has been limited by its adrenal
toxicity. Although suramin did not affect chondrocyte viability
at the concentrations and durations tested here, its toxicity
profile would prevent its systemic use in patients with OA. It
would also be undesirable to increase TIMP-3 levels system-
ically, since metalloproteinase activity is required for numer-
ous physiologic processes, including wound healing and
angiogenesis. It would thus be necessary to target suramin
derivatives to cartilage, for example, through use of a
cartilage-targeting peptide (Rothenfluh et al., 2008). Our
limited scan of suramin analogs identified a more effective
analog and suggested some basic structure-activity require-
ments for activity, indicating the potential for engineering
more effective variants with improved safety profiles. We thus
propose suramin as a promising scaffold for the development
of novel therapeutics to target osteoarthritic cartilage loss.
retinoic acid (1 mM, 30 hours) in the presence of either a TIMP-3 antibody (MAB973, 50 mg/ml) or an isotype control (mouse IgG1, 50 mg/ml). Aggrecan
degradation was quantified using the DMMB assay (mean6 S.D., n = 4; **P # 0.01; ***P # 0.001 by two-way ANOVA with Bonferroni’s correction).
ns, not significant; RA, retinoic acid.
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Fig. 4. Suramin analog NF-279 shows improved ability to block TIMP-3 uptake and to protect cartilage. (A) Porcine cartilage explants were treated with
retinoic acid (1 mM) and/or suramin analogs (200 mg/ml) for 48 hours. Cartilage degradation was assessed by quantifying aggrecan fragments (mean 6
S.D., n = 3; ***P # 0.001 by two-way ANOVA with Bonferroni’s correction) released into the medium using the DMMB assay. (B) Glycosaminglycan-
binding 96-well plates were coated with 10 mg/ml suramin (red circles, EC50 = 1.90 6 0.21 nM), NF279 (green triangles, EC50 = 0.85 6 0.09 nM), NF110
(filled boxes, EC50 = 6.88 6 0.96 nM), NF157 (filled triangles, EC50 = 1.55 6 0.11 nM), NF449 (filled diamonds, EC50 = 4.66 6 0.69 nM), NF023 (open
circles, EC50 = 26.5 6 7.5 nM), NF340 (open squares, EC50. 100 nM), or NF546 (open triangles, EC50. 100 nM) in PBS and blocked in 0.2% gelatin in
PBS. Wells were then incubated with TIMP-3 (0.4–50 nM) and binding was detected using an M2 anti-FLAG antibody (mean 6 S.E., n = 3 technical
repeats). (C) HTB94 chondrosarcoma cells were cultured in the presence of suramin analogs (200mg/ml) for 36 hours and TIMP-3 levels in the conditioned
medium were evaluated by Western blotting and quantified by densitometry (mean 6 S.D., n = 4, suramin defined as 100%; ***P # 0.001 by one-way
ANOVA with Bonferroni’s correction). (D) For each analog, TIMP-3 accumulation [from (C)] was plotted against the log10 of analog affinity for TIMP-3
[EC50 from (B)] and Pearson correlation coefficients were calculated using GraphPad Prism. (E) For each analog, TIMP-3 accumulation [from (C)] was
plotted against aggrecan release [from (A)] and Pearson correlation coefficients were calculated using GraphPad Prism. (F) Structural formulae of
suramin and its analog, NF279. RA, retinoic acid.
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